Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Authors:
Izanne Roos Emmanuelle Leray Federico Frascoli Romain Casey J William L Brown Dana Horakova Eva K Havrdova Maria Trojano Francesco Patti Guillermo Izquierdo Sara Eichau Marco Onofrj Alessandra Lugaresi Alexandre Prat Marc Girard Pierre Grammond Patrizia Sola Diana Ferraro Serkan Ozakbas Roberto Bergamaschi Maria José Sá Elisabetta Cartechini Cavit Boz Franco Granella Raymond Hupperts Murat Terzi Jeannette Lechner-Scott Daniele Spitaleri Vincent Van Pesch Aysun Soysal Javier Olascoaga Julie Prevost Eduardo Aguera-Morales Mark Slee Tunde Csepany Recai Turkoglu Youssef Sidhom Riadh Gouider Bart Van Wijmeersch Pamela McCombe Richard Macdonell Alasdair Coles Charles B Malpas Helmut Butzkueven Sandra Vukusic Tomas Kalincik

Brain 2020 09;143(9):2742-2756

CORe, Department of Medicine, University of Melbourne, Melbourne, 3050, Australia.

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 12 and 30 weeks. The duration of therapeutic lag for disability progression was calculated for seven therapies and ranged between 30 and 70 weeks. Significant differences in the pre- versus post-treatment annualized relapse rate were present for all therapies apart from intramuscular interferon beta-1a. In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progression in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience early on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag.

Download full-text PDF

 Source
http://dx.doi.org/10.1093/brain/awaa231DOI Listing
September 2020

Publication Analysis

Top Keywords

multiple sclerosis
24
therapeutic lag
24
disease activity
16
treatment start
16
disability progression
16
duration therapeutic
12
treatment
10
externally validated
8
ranged weeks
8
lag relapses
8
stabilization treatment
8
treatment epochs
8
annualized relapse
8
therapies ranged
8
calculated therapies
8
progression events
8
multiple
6
lag
6
sclerosis
6
therapeutic
6

Keyword Occurance

Similar Publications

A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.

Authors:
D Ferraro P Annovazzi R Lanzillo M Calabrese R Fantozzi G De Luca C Cordioli D Paolicelli P Ragonese A Gajofatto S Lo Fermo P Cavalla C Tortorella I Pesci A Gallo F Pinardi M Di Filippo G T Maniscalco V Nociti M Radaelli V Tomassini M C Buscarinu M Moccia V Camera E Cocco C Gasperini C Solaro

J Neurol Sci 2021 Mar 27;424:117430. Epub 2021 Mar 27.

Rehabilitation Department, Mons. L. Novarese, Moncrivello, Vercelli, Italy.

The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number of reasons including high recurrence rates, lack of MS-specific treatment guidelines and uncertainties about pain pathophysiology. Aim of this cross-sectional, multicentre survey was to gather information on the current treatment modalities and options of MS-related TN across 23 Italian MS centres. Initial medical management (carbamazepine or oxcarbazepine) of MS-related TN was fairly homogeneous throughout Italian centres. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients.

Authors:
Eloy Roura Grégory Maclair Magí Andorrà Ferran Juanals Irene Pulido-Valdeolivas Albert Saiz Yolanda Blanco Maria Sepulveda Sara Llufriu Eloy Martínez-Heras Elisabeth Solana Elena H Martinez-Lapiscina Pablo Villoslada

Neuroimage Clin 2021 Mar 29;30:102653. Epub 2021 Mar 29.

Institut d'Investigacions Biomèdiques August Pi Sunyer - Hospital Clinic, University of Barcelona, Spain; Stanford University, Stanford, CA, USA. Electronic address:

Background: Fractal geometry measures the morphology of the brain and detects CNS damage. We aimed to assess the longitudinal changes on brain's fractal geometry and its predictive value for disease worsening in patients with Multiple Sclerosis (MS).

Methods: We prospectively analyzed 146 consecutive patients with relapsing-remitting MS with up to 5 years of clinical and brain MRI (3 T) assessments. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment.

Authors:
Vasiliki Pantazou Caroline Pot Renaud Du Pasquier Géraldine Le Goff Marie Théaudin

Mult Scler Relat Disord 2021 Mar 21;51:102918. Epub 2021 Mar 21.

Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland. Electronic address:

Background: Discontinuing fingolimod (FTY) in older patients is a growing concern with little evidence supporting the decision to pursue treatment and reasonable doubt for disease reactivation after withdrawal.

Objective: To estimate the incidence of recurrence of disease activity (RDA) and rebound after FTY withdrawal in patients older than 50 years.

Methods: Retrospective analysis of all MS patients in our clinic who discontinued FTY after at least 6 months of treatment, according to disease activity on FTY and age at discontinuation. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Fasudil enhances the phagocytosis of myelin debris and the expression of neurotrophic factors in cuprizone-induced demyelinating mice.

Authors:
Zhi-Bin Ding Qing-Xian Han Qing Wang Li-Juan Song Guo-Guo Chu Min-Fang Guo Zhi Chai Jie-Zhong Yu Bao-Guo Xiao Xin-Yi Li Cun-Gen Ma

Neurosci Lett 2021 Apr 7:135880. Epub 2021 Apr 7.

Department of Neurology, Bethune Hospital Affiliated to Shanxi Medical University, Taiyuan, 030032, China; The Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine, Research Center of Neurobiology, Shanxi University of Chinese Medicine, Taiyuan, 030024, China; Institute of Brain Science, Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases, Medical School of Shanxi Datong University, Datong, 037009, China. Electronic address:

Multiple sclerosis (MS) is mainly associated with the neuroinflammation and demyelination in the central nervous system (CNS), in which the failure of remyelination results in persistent neurological dysfunction. Fasudil, a typical Rho kinase inhibitor, has been exhibited beneficial effects on several models of neurodegenerative disorders. In this study, we showed that Fasudil promoted the uptake of myelin debris by microglia via cell experiments and through a cuprizone (CPZ)-induced demyelinating model. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Clinical features, visual outcome, and poor prognostic factors in occlusive retinal vasculitis.

Authors:
Miaoli Lin Stephen D Anesi Peter Y Chang Laura Eggenschwiler Ambika Manhapra Marisa Walsh C Stephen Foster

Can J Ophthalmol 2021 Apr 7. Epub 2021 Apr 7.

Massachusetts Eye Research and Surgery Institution, Waltham, Mass.; Ocular Immunology and Uveitis Foundation, Waltham, Mass.; Harvard Medical School, Boston, Mass.. Electronic address:

Objective: To investigate the clinical features, treatment, and visual outcome of occlusive retinal vasculitis (ORV), with a focal analysis on prognostic factors associated with poor visual outcome.

Methods: We conducted a retrospective cohort study in patients diagnosed with ORV with at least 6 months of follow-up. Demographic data, ocular features, best corrected visual acuity (BCVA), fluorescein angiography, therapy regimens, and outcomes were collected from the Massachusetts Eye Research and Surgery Institution database from 2006 to 2017. Read More

View Article and Full-Text PDF
April 2021
Similar Publications